The UK National Screening Committee (UKNSC) has advised against routine population-wide prostate cancer screening using the PSA test, stating it would likely cause more harm than good.
The committee's draft recommendation suggests screening only men with BRCA1 and BRCA2 genetic mutations every two years between the ages of 45 and 61, due to their significantly higher risk.
Extensive screening for Black men and those with a family history of prostate cancer was not recommended, citing a current lack of sufficient data and evidence for these groups.
Health Secretary Wes Streeting confirmed he would consider the findings, aiming for earlier diagnosis and quicker treatment while balancing this against the potential harms of wider screening.
The UKNSC will collaborate with Prostate Cancer UK's Transform trial, which is investigating combined screening techniques, with results expected within two years to inform future recommendations.